doi: 10.1021/acs.jmedchem.3c02423.
- PMID: 38885438
- DOI: 10.1021/acs.jmedchem.3c02423
Abstract
The human orphan G protein-coupled receptor GPR18, activated by Δ9-tetrahydrocannabinol (THC), constitutes a promising drug target in immunology and cancer. However, studies on GPR18 are hampered by the lack of suitable tool compounds. In the present study, potent and selective GPR18 agonists were developed showing low nanomolar potency at human and mouse GPR18, determined in β-arrestin recruitment assays. Structure-activity relationships were analyzed, and selectivity versus cannabinoid (CB) and CB-like receptors was assessed. Compound 51 (PSB-KK1415, EC50 19.1 nM) was the most potent GPR18 agonist showing at least 25-fold selectivity versus CB receptors. The most selective GPR18 agonist 50 (PSB-KK1445, EC50 45.4 nM) displayed >200-fold selectivity versus both CB receptor subtypes, GPR55, and GPR183. The new GPR18 agonists showed minimal species differences, while THC acted as a weak partial agonist at the mouse receptor. The newly discovered compounds represent the most potent and selective GPR18 agonists reported to date.
Similar articles
-
Med Chem. 2023;19(9):838-847. doi: 10.2174/1573406419666230406095220.PMID: 37038675 Review.
-
ACS Med Chem Lett. 2020 Jun 17;11(10):2024-2031. doi: 10.1021/acsmedchemlett.0c00208. eCollection 2020 Oct 8.PMID: 33062188 Free PMC article.
-
Biomolecules. 2020 Apr 29;10(5):686. doi: 10.3390/biom10050686.PMID: 32365486 Free PMC article.
-
Eur J Med Chem. 2018 Jul 15;155:381-397. doi: 10.1016/j.ejmech.2018.05.050. Epub 2018 Jun 1.PMID: 29902723
-
Screening for Selective Ligands for GPR55 – Agonists.
2010 Sep 29 [updated 2011 May 26]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–.PMID: 22091480 Free Books & Documents. Review.
